Citi analyst Joanne Wuensch has reiterated their neutral stance on ZBH stock, giving a Hold rating today.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
Joanne Wuensch’s rating is based on a combination of factors surrounding Zimmer Biomet Holdings’ recent performance and future outlook. The company reported better-than-expected results for the first quarter of 2025, with revenue slightly surpassing consensus estimates and earnings per share exceeding expectations. However, despite these positive results, the company faces challenges such as a reduction in earnings per share guidance for the full year, partly due to tariff headwinds and integration costs from the Paragon 28 acquisition.
Looking ahead, while management has raised its revenue growth guidance, the impact of tariffs remains a concern, with a significant headwind expected in the latter half of the year. Additionally, the company is navigating a complex landscape with various moving parts, including currency fluctuations and competitive dynamics. These factors contribute to a cautious outlook, leading to a Hold rating as the company works to offset these challenges and capitalize on its growth opportunities.
Based on the recent corporate insider activity of 30 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of ZBH in relation to earlier this year.